Awaiting product image

The Emerging Cancer Vaccine Market, 2nd Edition

$1,200.00 – $7,000.00

SKU: KLI1190824 Categories: , Pages: 270

Description

Propelled by advances in molecular biology, the cancer vaccine industry is poised for unprecedented growth. This second edition of Kalorama’s groundbreaking 2003 study completely updates the market data and reviews the technological, clinical, and business trends that have shaped and reshaped this emerging field.

Specific segments covered in the report include:

  • Cervical cancer,
  • Colorectal cancer,
  • Lung cancer,
  • Lymphoma,
  • Melanoma,
  • Prostate cancer, and
  • Other cancers for which vaccines are in development.

Each market segment provides an overview, descriptions of products available and in development, market estimates and forecasts for 2007-2012 by product, and competitive analysis of leading developers, including forecasted market share for 2012. The report also includes statistical information on cancers by type worldwide and in the United States. Profiles of the following developers and marketers are also included:

  • Advaxis, Inc.
  • Antigenics, Inc.
  • Aphton Corporation
  • AVAX Technologies, Inc.
  • Biomira, Inc.
  • Biovest International, Inc.
  • Cell Genesys, Inc.
  • Dendreon Corporation
  • Favrille, Inc.
  • GenMax Corporation
  • Genitope Corporation
  • Genzyme
  • Geron Corporation
  • GlaxoSmithKline
  • IDM
  • Intracel
  • Large Scale Biology Corporation
  • Medarex, Inc.
  • MedImmune, Inc.
  • Merck & Company, Inc.
  • Northwest Biotherapeutics
  • Oxford Biomedica, Plc
  • Pharmexa Group
  • Progenics Pharmaceuticals, Inc.
  • Therion Biologics Corporation
  • Vical, Inc.
  • YM Biosciences, Inc.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. Kalorama Information conducted interviews with dozens of key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and development representatives.

Table of Contents

Executive Summary

  • Introduction
  • Scope and Methodology
  • Size and Growth of the Market
  • Issues and Trends Affecting Market
  • Competitive Analysis
  • Profiles

Introduction

  • History and Growth of the Cancer Treatment Market
  • Types of Vaccines
    • Antigen/Adjuvant Vaccines
    • Whole Cell Tumor Vaccines
    • Dendritic Cell (DC) Vaccines
    • Viral Vectors and DNA Vaccines
    • Idiotype Vaccines
    • Types of Therapeutic Vaccines
    • Patient-Specific Vaccines
    • Prostate Specific Antigen
    • Sialyl Tn
    • Heat Shock Proteins
    • Ganglioside Molecules
    • Carcinoembryonic Antigen (CEA)
    • MART-1
    • Tyrosinase
    • Adjuvants
  • Industry Structure
  • Demographics and Statistics

Cervical Cancer Vaccines

  • Overview
  • Vaccines Products
    • On the Market
    • Gardasil
    • In Development
    • Cervarix
    • TG 4001
    • Lovaxin C
    • HspE7
  • Market and Product Launch Forecasts
  • Potential Competitors and Analysis, 2012

Colon/Rectal Cancer Vaccines

  • Overview
  • Vaccine Products
    • On the Market
    • OncoVAX
    • In Development
    • OncoVAX
    • ALVAC -CEA/B7.1
    • TroVAX
    • Avicine
    • Ep2101
    • IGN 101
    • Collidem
    • Lapuleucel-T
    • Oncophage
    • CRS-100
    • MDX-1307
    • Tumor Associated Antigen Therapeutic Vaccine-HER-2 and CEA
  • Market and Product Launch Forecasts
  • Potential Competitors and Analysis, 2012

Lung Cancer Vaccines

  • Overview
  • Vaccine Products in Development
    • Stimuvax
    • ICN-101
    • GV-1001
    • Ep2101
    • Oncophage
    • PanVac + Taxotere
    • MAGE-3 Peptide
    • INGN 225
    • TG 4010
    • L-VAX
    • ALT-110
    • CEA-TriCom
    • DC Vax
    • Lapuleucel-T
    • L523S
  • Market and Product Launch Forecasts
  • Potential Competitors and Analysis, 2012

Lymphoma Vaccines

  • Overview
  • Vaccines in Development
    • MyVax
    • BiovaxID
    • FavId
    • Oncophage
    • TG4010
    • FAV-201
    • Non-Hodgkin’s Lymphoma Vaccine
    • BGLP40 Vaccine
  • Market and Product Launch Forecasts
  • Potential Competitors and Analysis, 2012

Melanoma Vaccines

  • Overview
  • Vaccines on the Market
  • Vaccines in Development
    • M-VAX
    • GMK
    • Allovectin-7
    • MDX-010/MDX-1379
    • Oncophage
    • Canvaxin
    • Melacine
    • Triple Peptide Vaccine
    • MART-1/Melan-A
    • MAGE-3 Peptide
    • TriCom
    • Tyrosinase Peptide
    • Uvidem
    • Melan-A/MART-1 and gp100
    • ALVAC -CEA/B7.1
    • MDX-1106/ONO-4538
  • Market and Product Launch Forecasts
  • Potential Competitors and Analysis, 2012

Prostate Cancer Vaccines

  • Overview
  • Vaccines in Development
    • Provenge
    • DC Vax-Prostate
    • GVAX
    • Stimuvax
    • GnRH Pharmaccine Therapeutic Vaccine
    • IGN-101
    • Pentrix
    • PROSTVAC-VF
    • Telomerase Cancer Vaccine
    • TG4010
    • Norelin
    • PSMA RS Protein Vaccine
    • Luteinizing Hormone Releasing Hormone
    • ALT-110
  • Market and Product Launch Forecasts
  • Potential Competitors and Analysis, 2012

Various Cancer Vaccines

  • Overview
    • Bladder Cancer
    • Breast Cancer
    • Stomach Cancer
    • Liver Cancer
    • Pancreatic Cancer
    • Kidney Cancer
    • Leukemia
    • Multiple Myeloma
    • Neuroblastoma
    • Ovarian Cancer
    • Sarcoma
  • Vaccines on the Market
    • BCG Therapy (OncoTICE- Organon Teknika; Immucyst-Sanofi Pasteur; Pacis-Shire Pharmaceuticals)
  • Vaccines in Development
    • Oncophage
    • Insegia
    • Avicine
    • MyVax
    • PANVAC-VF
    • Theratope
    • Bexidem
    • AG-858
    • DC Vax
    • GVAX
    • IGN-101
    • O-VAX Autologous Cell Vaccine
    • PX 104.1
    • TroVAX
    • Dendritic Cell/Tumor Cell Fusion Cancer Vaccine
    • INGN 225
    • ALT-110
    • DNA Cancer Vaccine
    • GV 1001
    • Lapuleucel-T
    • Lovaxin C
    • MDX-1307
    • Telomerase
  • Market and Product Launch Forecasts
  • Potential Competitors and Analysis, 2012

Issues and Trends

  • Early Detection and Screening
  • Monoclonal Antibodies and Therapeutic Vaccines
  • Political and Social Pressure
  • Insurance and Reimbursement Issues
  • Personalized Medicine
  • Pharmacogenomics
  • Vaccine strategies
  • New Genetic Technique
  • Future Growth in Vaccines

Total Market Forecasts

  • Overview
  • Total market Size and Forecast
  • Competitor Analysis
  • Market Analysis

Corporate Profiles

  • Introduction
  • Advaxis, Inc.
  • Antigenics, Inc.
  • Aphton Corporation
  • Avax Technologies, Inc.
  • Biomira, Inc.
  • Biovest International, Inc.
  • Cell Genesys, Inc.
  • Dendreon Corporation
  • Favrille, Inc.
  • GeneMax Corporation
  • Genitope Corporation
  • Genzyme Molecular Oncology
  • Geron Corporation
  • GlaxoSmithKline plc
  • IDM Pharma, Inc.
  • Intracel Resources LLC
  • Large Scale Biology Corporation
  • Medarex, Inc.
  • MedImmune, Inc.
  • Merck & Company, Inc.
  • Northwest Biotherapeutics, Inc.
  • Oxford BioMedica plc
  • Pharmexa Group
  • Progenics Pharmaceuticals, Inc.
  • Therion Biologics Corporation
  • Vical, Inc.
  • YM BioSciences, Inc.

Company Directory

List of Exhibits

Chapter One: Executive Summary

  • Figure 1-1: Market Summary: Cancer Vaccines Revenues, 2007-2012

Chapter Two: Introduction

  • Table 2-1: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2005 and 2020
  • Figure 2-1: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2005 and 2020
  • Table 2-2: Estimated and Projected World Cancer Mortality by Selected Types of Cancer, 2005 and 2020
  • Figure 2-2: Estimated and Projected World Cancer Mortality by Selected Types of Cancer, 2005 and 2020
  • Table 2-3: Total Cancer Incidence by Sex and Country, 2006 Estimates
  • Figure 2-3: Total Cancer Incidence by Sex and Country
  • Table 2-4: Estimated Cancer Incidence by World Region and Type of Cancer
  • Figure 2-4: Estimated Cancer Incidence by World Regions
  • Table 2-5: World Population by Selected Geographical Region, 2006-2050
  • Figure 2-5: World Population by Selected Geographical Region, 2006-2050
  • Table 2-6: Estimated World Population by Age and Geographical Region, 2006
  • Figure 2-6: Estimated World Population by Age and Geographical Region, 2006
  • Table 2-7: Life Expectancy at Birth by Selected Countries, Projected 2006
  • Table 2-8: United States Life Expectancy at Birth, 1990 and 2000; Projections, 2006 and 2010
  • Figure 2-7: United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2002
  • Figure 2-8: United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2003

Chapter Three: Cervical Cancer Vaccines

  • Table 3-1: Estimated U.S. and World Incidence and Mortality of Cervical Cancer
  • Figure 3-1: Estimated U.S. and World Incidence and Mortality of Cervical Cancer
  • Table 3-2: Cervical Cancer Vaccines in the Pipeline (Product, Developer, Phase, Earliest Approval Date)
  • Table 3-3: The World Market for Cervical Cancer Vaccines Revenues and Growth Rate 2007-2012
  • Figure 3-2: Trending in the Cervical Cancer Vaccine Market 2007-2012
  • Figure 3-3: The Projected Cervical Cancer Vaccine Market in Comparison to Traditional Therapeutics, 2012
  • Table 3-4: The Cervical Cancer Vaccine Market Projected Revenues and Market Share by Leading Supplier 2012
  • Figure 3-4: Anticipated Sales by Product and Year for Cervical Cancer Vaccines by Product, 2007-2012

Chapter Four: Colon/Rectal Cancer Vaccines

  • Table 4-1: Estimated U.S. and World Incidence and Mortality of Colon/Rectal Cancer
  • Figure 4-1: Estimated U.S. and World Incidence and Mortality of Colon/Rectal Cancer
  • Table 4-2: Colon/Rectal Cancer Vaccines in the Pipeline (Product, Developer, Phase, Earliest Approval Date)
  • Table 4-3: The World Market for Colon/Rectal Cancer Vaccines Revenues and Growth Rate 2007-2012
  • Figure 4-2: Trending in the Colon/Rectal Cancer Vaccine Market, 2009-2012
  • Figure 4-3: The Colon/Rectal Cancer Vaccine Market in Comparison to Traditional Therapies, 2012
  • Table 4-4: The Colon/Rectal Cancer Vaccine Market Projected Revenues and Market Share by Leading Supplier 2012
  • Figure 4-4: Anticipated Sales by Product and Year for Colon/Rectal Cancer Vaccines, 2007-2012

Chapter Five: Lung Cancer Vaccines

  • Table 5-1: Types of Primary Lung Cancer, Risk Factors, Percent of Cases
  • Table 5-2: Cancer Vaccines: Estimated World Incidence and Mortality of Lung Cancer (thousands)
  • Figure 5-1: Estimated U.S. and World Incidence and Mortality of Lung Cancer
  • Table 5-3: Lung Cancer Vaccines in the Pipeline (Product, Developer, Phase, Earliest Approval Date)
  • Table 5-4: The World Market for Lung Cancer Vaccines Revenues and Growth Rate 2007-2012
  • Figure 5-2: Trending in the Lung Cancer Vaccine Market, 2009-2012
  • Figure 5-3: The Lung Cancer Vaccine Market in Comparison to Traditional Therapies, 2012
  • Table 5-5: The Lung Cancer Vaccine Market Projected Revenues and Market Share by Leading Supplier 2012
  • Figure 5-4: Anticipated Sales by Product and Year for Lung Cancer Vaccines 2009-2012

Chapter Six: Lymphoma Vaccines

  • Table 6-1: Classification of Non-Hodgkin’s Lymphomas
  • Table 6-2: Estimated U.S. and World Incidence and Mortality of Lymphoma
  • Figure 6-1: Estimated U.S. and World Incidence and Mortality of Lymphoma
  • Table 6-3: Lymphoma Vaccines in the Pipeline (Product, Developer, Phase, Earliest Approval Date)
  • Table 6-4: The World Market for Lymphoma Vaccines Revenues and Growth Rate 2007-2012
  • Figure 6-2: Trending in the Lymphoma Vaccine Market, 2008-2012
  • Figure 6-3: The Lymphoma Vaccine Market in Comparison to Traditional Therapies, 2012
  • Table 6-5: The Lymphoma Vaccine Market Projected Revenues and Market Share by Leading Supplier 2012
  • Figure 6-4: Anticipated Sales by Product and Year for Emerging Lymphoma Vaccines, 2008-2012

Chapter Seven: Melanoma Vaccines

  • Table 7-1: Malignant Conditions of the Skin
  • Table 7-2: Estimated U.S. and World Incidence and Mortality of Melanoma
  • Figure 7-1: Estimated U.S. and World Incidence and Mortality of Melanoma
  • Table 7-3: Melanoma Vaccines in the Pipeline (Product, Developer, Phase, Earliest Approval Date)
  • Table 7-4: The World Market for Melanoma Vaccines Revenues and Growth Rate 2007-2012
  • Figure 7-2: Trending in the Melanoma Vaccine Market, 2007-2012
  • Figure 7-3: The Melanoma Vaccine Market in Comparison to Traditional Therapies, 2012
  • Table 7-5: The Melanoma Vaccine Market Projected Revenues and Market Share by Leading Supplier 2012
  • Figure 7-4: Anticipated Sales by Product and Year for Melanoma Vaccines 2007-2012

Chapter Eight: Prostate Cancer Vaccines

  • Table 8-1: Estimated U.S and World Incidence and Mortality of Prostate Cancer
  • Figure 8-1: Estimated U.S. and World Incidence and Mortality of Prostate Cancer
  • Table 8-2: Prostate Cancer Vaccines in the Pipeline (Product, Developer, Phase, Earliest Approval Date)
  • Table 8-3: The World Market for Prostate Cancer Vaccines Revenues and Growth Rate 2007-2012
  • Figure 8-2: Trending in the Prostate Cancer Vaccine Market, 2008-2012
  • Figure 8-3: The Prostate Cancer Vaccine Market in Comparison to Traditional Therapies, 2012
  • Table 8-4: The Prostate Cancer Vaccine Market Projected Revenues and Market Share by Leading Supplier 2012
  • Figure 8-4: Anticipated Sales by Product and Year for Prostate Cancer Vaccines, 2007-2012

Chapter Nine: Various Cancer Vaccines

  • Table 9-1: Types of Leukemia (Incidence, Age of Onset, Clinical Manifestations)
  • Table 9-2: Estimated U.S. World Incidence and Mortality of Various Cancers (Bladder, Breast, Kidney, Leukemia, Liver, Neuroblastoma, Ovarian, Pancreatic, Stomach)
  • Figure 9-1: Estimated U.S. and World Incidence and Mortality of Various Cancer
  • Table 9-3: Various Cancer Vaccines in the Pipeline (Product, Developer, Phase, Cancer Type, Earliest Approval Date)
  • Table 9-4: The World Market for Other Cancer Vaccines Revenues and Growth Rate 2007-2012
  • Figure 9-2: Trending in the Market for Other Cancer Vaccines 2007-2012
  • Figure 9-3: The Emerging Various Cancer Vaccine Market in Comparison to Traditional Therapies, 2012
  • Table 9-5: Projected Revenues and Market Share of Leading Suppliers of Other Cancer Vaccines 2012
  • Figure 9-4: Anticipated Sales by Product and Year for Other Cancer Vaccines, 2007-2012

Chapter Ten: Issues and Trends

  • Table 10-1: Cancer Detection Tests

Chapter Eleven: Total Market Forecasts

  • Table 11-1: Cancer Vaccines Market by Cancer Type, 2007-2012
  • Figure 11-1: Trending in the Cancer Vaccines Market, 2007-2012
  • Figure 11-2: Share of the Cancer Vaccine by Vaccine Indication, 2012
  • Table 11-2: Suppliers/Developers of Vaccines by Cancer Type and Development Phase
  • Figure 11-3: Number of Cancer Vaccine Trials by Cancer Type
  • Figure 11-4: Cancer Vaccine Trials, Distribution by Cancer Type, 2006
  • Figure 11-5: Cancer Vaccines in Development by Type and Phase
  • Figure 11-6: Cancer Vaccines in Developments by Phase, 2006

 

Related products

Medical Imaging Markets, Volume III – UltrasoundClinical Diagnostics in India – Market Sector Analyses and Participant...